Related Experiment Video
Updated: Mar 18, 2026
Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
Published on: January 24, 2020
Lethal toxin-equipped effector cells for the potential treatment of cancer
Alexander H Pearlman1,2, Brian J Mog1,2, Michael S Hwang1,2
1Ludwig Center for Cancer Genetics and Therapeutics and Lustgarten Laboratory, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287.
Abstract:
Lethal toxins could become potent therapies against cancer, but their clinical utility is limited by adverse events upon systemic administration. These could be reduced if the toxins were delivered by effector cells that specifically infiltrate cancers, thereby releasing toxins locally into the tumor microenvironment. One of the challenges underlying this strategy is that cells delivering toxins would have to be resistant to them. We address this obstacle by showing that effectors derived from transformed human cell lines genetically engineered for resistance to bacterial adenosine diphosphate ribosylating toxins (ADPRTs), including Pseudomonas aeruginosa exotoxin A (PE), can produce targeted immunotoxins that specifically kill cancer cells expressing cognate tumor-associated antigens. Resistance to immunotoxins was achieved by knockout of genes in the diphthamide biosynthesis pathway (DPH1-4) required for the posttranslational modification of eukaryotic elongation factor 2 (EEF2) that is the target of ADPRTs or by mutation of EEF2 itself. We show that engineering resistance to ADPRTs, one of the most potent toxins acting on human cells, is essential to achieve robust function of armored effector cell lines. This work establishes a critical step on the path to equip effector cells with the ability to deliver powerful toxins to cancer cells and introduces a platform to investigate extension to primary autologous or allogeneic therapeutic cell types.
Insights
Engineered cells resist lethal toxins, enabling targeted cancer therapy. This approach uses armored effector cells to deliver potent toxins directly to tumors, minimizing side effects.
Area of Science:
- Biotechnology
- Cancer Therapeutics
- Molecular Biology
Background:
- Lethal toxins show promise as cancer therapies but cause severe side effects when administered systemically.
- Targeted delivery of toxins by effector cells to the tumor microenvironment could mitigate adverse events.
- A key challenge is ensuring effector cells are resistant to the toxins they deliver.
Purpose of the Study:
- To engineer human cell lines resistant to bacterial adenosine diphosphate ribosylating toxins (ADPRTs).
- To develop a platform for creating targeted immunotoxins delivered by armored effector cells.
- To demonstrate the feasibility of using toxin-resistant effector cells for cancer treatment.
Main Methods:
- Genetically engineered transformed human cell lines for resistance to ADPRTs, including *Pseudomonas aeruginosa* exotoxin A (PE).
- Achieved resistance by knocking out diphthamide biosynthesis pathway genes (*DPH1-4*) or mutating eukaryotic elongation factor 2 (*EEF2*).
- Utilized engineered cells to produce targeted immunotoxins against cancer cells expressing specific tumor-associated antigens.
Main Results:
- Engineered effector cells demonstrated resistance to potent ADPRTs.
- These armored cells successfully produced targeted immunotoxins that specifically killed cancer cells.
- Resistance engineering is crucial for the robust function of effector cell-based cancer therapies.
Conclusions:
- Genetically engineering effector cells for toxin resistance is essential for developing targeted cancer immunotherapies.
- This study presents a novel platform for creating potent, cancer-specific immunotoxins.
- The approach paves the way for extending this strategy to primary therapeutic cell types.
More Related Videos
08:02In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
Published on: September 23, 2021
13:59High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023
Related Concept Videos
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...